"There's millions of dollars going to AIDS research from some many
different directions. From governments, music concerts, individuals, etc.
Just imagine what could possibly happen. If the big pharma solves the problem,
there will be no new income. If it is not just AIDS causing the symptoms in
Africa, they will never find the solution as long as they restrict their
research to Africa. They keep trying to find things that will "cure"
the symptoms. The virus seems to still be a mystery from what I read. Hopefully,
MMS will help in some fashion. If the virus mutates with drugs, it will not do
so with MMS. The problem might be that it is too aggressive and too fast
multiplying for MMS."
90% of the funding for AIDS research in the AIDS Research Alliance is from
pharmaceuticals. That's not just a token contribution.
In 2006, the Board of Directors of AIDS
Research Alliance adopted a Strategic Plan that will serve as an
organizational road map for the next five years. The data used to create
the Plan was gathered from internal and external stakeholders, including current
and past ARA staff, donors, board members,
members of the Institutional Review Board and Scientific Advisory Committee,
leaders in other scientific organizations, physicians specializing in HIV and
people in the community at large who have relationships with ARA.
Approximately 200 companies and organizations perform research for the
treatment, prevention and eradication of HIV/AIDS. While pharmaceutical
companies and biotech firms make up only 35% of these, they represent a
majority of the influence in HIV/AIDS research and are responsible for
approximately 90% of all spending in the field. The other 65% are
mostly universities and large non-profit research institutions that focus on
questions of basic research as opposed to drug development. Due to an
overwhelming dependence on government funding, they are limited by regulatory
burdens and a tendency toward institutional conservatism that keeps them from
pushing their research beyond accepted political boundaries.